Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2008 3
2009 2
2010 1
2011 1
2012 1
2014 1
2015 1
2016 4
2017 2
2018 2
2019 1
2020 2
2021 9
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer.
Pignata S, Bookman M, Sehouli J, Miller A, Penson RT, Taskiran C, Anderson C, Hietanen S, Myers T, Madry R, Willmott L, Lortholary A, Thomes-Pepin J, Aghajanian C, McCourt C, Stuckey A, Wu X, Nishio S, Copeland LJ, He Y, Molinero L, Patel S, Lin YG, Khor VK, Moore KN. Pignata S, et al. Among authors: madry r. Gynecol Oncol. 2023 Oct;177:20-31. doi: 10.1016/j.ygyno.2023.06.018. Epub 2023 Aug 23. Gynecol Oncol. 2023. PMID: 37625235 Clinical Trial.
Epithelial Ovarian Cancer-Varied Treatment Results.
Millert-Kalińska S, Przybylski M, Pruski D, Stawicka-Niełacna M, Mądry R. Millert-Kalińska S, et al. Among authors: madry r. Healthcare (Basel). 2023 Jul 17;11(14):2043. doi: 10.3390/healthcare11142043. Healthcare (Basel). 2023. PMID: 37510484 Free PMC article.
Uterine sarcoma - time is worth its weight in gold.
Pruski D, Millert-Kalińska S, Mądry R, Kotynia K, Pawełek T, Rusek D, Zmaczyński A, Jach R, Przybylski M. Pruski D, et al. Among authors: madry r. Pol J Pathol. 2023;74(1):59-62. doi: 10.5114/pjp.2023.127292. Pol J Pathol. 2023. PMID: 37306355 Free article.
Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial.
Pignata S, Oza A, Hall G, Pardo B, Madry R, Cibula D, Klat J, Montes A, Glasspool R, Colombo N, Pete I, Herrero Ibáñez A, Marín MR, Ilieva R, Timcheva C, Di Maio M, Blakeley C, Taylor R, Barnicle A, Clamp A. Pignata S, et al. Among authors: madry r. Gynecol Oncol. 2023 May;172:121-129. doi: 10.1016/j.ygyno.2023.03.019. Epub 2023 Apr 6. Gynecol Oncol. 2023. PMID: 37030280 Free article.
Genotyping of human papillomavirus DNA in Wielkopolska region.
Przybylski M, Pruski D, Millert-Kalinska S, Madry R, Lagiedo-Zelazowska M, Sikora J, Zmaczynski A, Baran R, Twardowska H, Horbaczewska A, Jach R. Przybylski M, et al. Among authors: madry r. Ginekol Pol. 2021 Sep 20. doi: 10.5603/GP.a2021.0165. Online ahead of print. Ginekol Pol. 2021. PMID: 34541643 Free article.
Expression of selected molecular factors in two types of endometrial cancer.
Markowska A, Gryboś A, Marszałek A, Bednarek W, Filas V, Gryboś M, Markowska J, Mądry R, Więckowska B, Nowalińska D, Szarszewska M. Markowska A, et al. Among authors: madry r. Adv Clin Exp Med. 2021 Oct;30(10):1057-1064. doi: 10.17219/acem/137383. Adv Clin Exp Med. 2021. PMID: 34510841 Free article.
The Effect of Endurance and Endurance-Strength Training on Bone Mineral Density and Content in Abdominally Obese Postmenopausal Women: A Randomized Trial.
Jamka M, Mądry E, Bogdański P, Kryściak J, Mądry R, Lisowska A, Ismagulova E, Gotz-Więckowska A, Chudzicka-Strugała I, Amanzholkyzy A, Walkowiak J. Jamka M, et al. Among authors: madry r. Healthcare (Basel). 2021 Aug 20;9(8):1074. doi: 10.3390/healthcare9081074. Healthcare (Basel). 2021. PMID: 34442211 Free PMC article.
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, Minar L, Melichar B, Hein A, Kieszko D, Pluta M, Spacek J, Bartos P, Wimberger P, Madry R, Markowska J, Streb J, Valha P, Hassan HIB, Pecen L, Galluzzi L, Fucikova J, Hrnciarova T, Hraska M, Bartunkova J, Spisek R. Cibula D, et al. Among authors: madry r. Gynecol Oncol. 2021 Sep;162(3):652-660. doi: 10.1016/j.ygyno.2021.07.003. Epub 2021 Jul 20. Gynecol Oncol. 2021. PMID: 34294416 Free article. Clinical Trial.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ. Pujade-Lauraine E, et al. Among authors: madry r. Lancet Oncol. 2021 Jul;22(7):1034-1046. doi: 10.1016/S1470-2045(21)00216-3. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143970 Clinical Trial.
33 results